Spyre Therapeutics, Inc. (SYRE) stock
SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
$101.46+7.65 (+8.15%)
Close on Nov 18, 2026Market cap $8.95BP/E –Yield –
Spyre Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Spyre Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $215.80M, up 21.9% year over year. For fiscal 2025 it was $171.65M, up 5.4% from the year before. Over ten years it grew 31.1% a year on average. The highest annual figure on record is $171.65M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $171.65M | +5.4% |
| FY2024 | Dec 31, 2024 | $162.79M | +81.9% |
| FY2023 | Dec 31, 2023 | $89.50M | +52.8% |
| FY2022 | Dec 31, 2022 | $58.58M | +2.6% |
| FY2021 | Dec 31, 2021 | $57.07M | -4.3% |
| FY2020 | Dec 31, 2020 | $59.64M | -7.7% |
| FY2019 | Dec 31, 2019 | $64.60M | +75.9% |
| FY2018 | Dec 31, 2018 | $36.72M | +60.9% |
| FY2017 | Dec 31, 2017 | $22.82M | +25.8% |
| FY2016 | Dec 31, 2016 | $18.14M | +58.4% |
| FY2015 | Dec 31, 2015 | $11.45M | +67.7% |
| FY2014 | Dec 31, 2014 | $6.83M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $65.50M | +63.2% |
| Q1 FY2026 | Mar 31, 2026 | $60.41M | +45.1% |
| Q4 FY2025 | Dec 31, 2025 | $44.64M | -11.6% |
| Q3 FY2025 | Sep 30, 2025 | $45.25M | +1.1% |
| Q2 FY2025 | Jun 30, 2025 | $40.15M | +23.0% |
| Q1 FY2025 | Mar 31, 2025 | $41.62M | +19.2% |
| Q4 FY2024 | Dec 31, 2024 | $50.48M | +49.9% |
| Q3 FY2024 | Sep 30, 2024 | $44.74M | +81.4% |
| Q2 FY2024 | Jun 30, 2024 | $32.64M | +87.7% |
| Q1 FY2024 | Mar 31, 2024 | $34.93M | +153.5% |
| Q4 FY2023 | Dec 31, 2023 | $33.68M | +136.3% |
| Q3 FY2023 | Sep 30, 2023 | $24.66M | +105.9% |
| Q2 FY2023 | Jun 30, 2023 | $17.39M | +13.1% |
| Q1 FY2023 | Mar 31, 2023 | $13.78M | -18.9% |
| Q4 FY2022 | Dec 31, 2022 | $14.25M | -15.1% |
| Q3 FY2022 | Sep 30, 2022 | $11.98M | -19.4% |
| Q2 FY2022 | Jun 30, 2022 | $15.37M | +13.2% |
| Q1 FY2022 | Mar 31, 2022 | $16.98M | +43.2% |
| Q4 FY2021 | Dec 31, 2021 | $16.78M | +6.5% |
| Q3 FY2021 | Sep 30, 2021 | $14.85M | +19.3% |
| Q2 FY2021 | Jun 30, 2021 | $13.58M | -19.5% |
| Q1 FY2021 | Mar 31, 2021 | $11.86M | -18.6% |
| Q4 FY2020 | Dec 31, 2020 | $15.76M | -10.3% |
| Q3 FY2020 | Sep 30, 2020 | $12.45M | -30.2% |
| Q2 FY2020 | Jun 30, 2020 | $16.87M | +13.9% |
| Q1 FY2020 | Mar 31, 2020 | $14.56M | +1.2% |
| Q4 FY2019 | Dec 31, 2019 | $17.57M | +48.9% |
| Q3 FY2019 | Sep 30, 2019 | $17.84M | +99.8% |
| Q2 FY2019 | Jun 30, 2019 | $14.81M | +62.3% |
| Q1 FY2019 | Mar 31, 2019 | $14.39M | +109.4% |
| Q4 FY2018 | Dec 31, 2018 | $11.80M | +103.7% |
| Q3 FY2018 | Sep 30, 2018 | $8.93M | +43.1% |
| Q2 FY2018 | Jun 30, 2018 | $9.12M | +56.3% |
| Q1 FY2018 | Mar 31, 2018 | $6.87M | +38.8% |
| Q4 FY2017 | Dec 31, 2017 | $5.79M | +22.1% |
| Q3 FY2017 | Sep 30, 2017 | $6.24M | +15.9% |
| Q2 FY2017 | Jun 30, 2017 | $5.84M | – |
| Q1 FY2017 | Mar 31, 2017 | $4.95M | – |
| Q4 FY2016 | Dec 31, 2016 | $4.74M | – |
| Q3 FY2016 | Sep 30, 2016 | $5.39M | – |
See a number that looks wrong?